A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-07-29
Adverse events
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-22 (study day 12); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-21 (study day 133); relationship: not assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-03-12 (study day 214); relationship: N
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-03-15 (study day 217); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-03 (study day 327); relationship: not assessed
Data queries
No data queries.